The resistance to interferons (IFNs) limits their anticancer therapeutic efficacy. Here we studied the evolution of an IFN-resistant state in vitro using melanoma cell lines. We found that the cells became less sensitive to antiproliferative effect of IFN-gamma after prolonged cultivation enabling us to isolate sensitive and resistant subclones of the parental line. We investigated transcription of signal transducer and activator of transcription (STAT) 1-6 and suppressor of cytokine signalling (SOCS) 1-3 genes, and phosphorylation of STAT 1 protein. The resistant subline (termed WM 1158R) differed from the sensitive subline (WM 1158S) by a constitutive expression of SOCS 3, lack or weak SOCS 1-3 activation following IFN-gamma, and short duration of cytokine activatory signal. Similar correlations were observed in additional melanoma lines differing in IFN sensitivities. At the protein level, IFN-gamma induced strong and prolonged STAT 1 activation at serine 727 (S727) in WM 1158R while in WM 1158S cells phosphorylation of this amino acid was much less pronounced. On the other hand, phosphorylation of tyrosine 701 (Y701) was stimulated regardless of the sensitivity phenotype. In conclusion, constitutive expression of SOCS 3 is correlated with attenuation of its induction following IFN treatment. These results suggest that progression of melanoma cells from IFN sensitivity to IFN insensitivity associates with changes in SOCS expression.

Institute of Biophysics Academy of Sciences of the Czech Republic v v i Kralovopolska 135 612 65 Brno Czech Republic

See more in PubMed

Alexander WS, Starr R, Fenner JE, Scott CL, Handman E, Sprigg NS, Corbin JE, Cornish AL, Darwiche R, Owczarek CM, Kay TW, Nicola NA, Hertzog PJ, Metcalf D, Hilton DJ (1999) SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98: 597–608 PubMed

Boudny V, Kocak I, Lauerova L, Kovarik J (2003) Interferon inducibility of STAT 1 activation and its prognostic significance in melanoma patients. Folia Biol (Praha) 49: 142–146 PubMed

Brierley MM, Fish EN (2005) Stats: multifaceted regulators of transcription. J Interferon Cytokine Res 25: 733–744 PubMed

Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, Russo A (2003) STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 197: 157–168 PubMed

Chawla-Sarkar M, Leaman DW, Jacobs BS, Borden EC (2002) IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. J Immunol 169: 847–855 PubMed

Chow M, Rubin H (2000) Clonal selection versus genetic instability as the driving force in neoplastic transformation. Cancer Res 60: 6510–6518 PubMed

Durbin JE, Hackenmiller R, Simon MC, Levy DE (1996) Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84: 443–450 PubMed

Evans MK, Yu CR, Lohani A, Mahdi RM, Liu X, Trzeciak AR, Egwuagu CE (2007) Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals. Oncogene 26: 1941–1948 PubMed

Fojtova M, Van Houdt H, Depicker A, Kovarik A (2003) Epigenetic switch from posttranscriptional to transcriptional silencing is correlated with promoter hypermethylation. Plant Physiol 133: 1240–1250 PubMed PMC

Fujimoto M, Naka T (2003) Regulation of cytokine signaling by SOCS family molecules. Trends Immunol 24: 659–666 PubMed

He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F, Jablons DM (2003) SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 100: 14133–14138 PubMed PMC

Hebenstreit D, Luft P, Schmiedlechner A, Duschl A, Horejs-Hoeck J (2005) SOCS-1 and SOCS-3 inhibit IL-4 and IL-13 induced activation of Eotaxin-3/CCL26 gene expression in HEK293 cells. Mol Immunol 42: 295–303 PubMed

Hilton DJ (1999) Negative regulators of cytokine signal transduction. Cell Mol Life Sci 55: 1568–1577 PubMed PMC

Jackson DP, Watling D, Rogers NC, Banks RE, Kerr IM, Selby PJ, Patel PM (2003) The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line. Melanoma Res 13: 219–229 PubMed

Komazaki T, Nagai H, Emi M, Terada Y, Yabe A, Jin E, Kawanami O, Konishi N, Moriyama Y, Naka T, Kishimoto T (2004) Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human pancreatic cancers. Jpn J Clin Oncol 34: 191–194 PubMed

Kortylewski M, Komyod W, Kauffmann ME, Bosserhoff A, Heinrich PC, Behrmann I (2004) Interferon-gamma-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals. J Invest Dermatol 122: 414–422 PubMed

Kovarik A, Fojtova M, Boudny V, Adamkova L, Lauerova L, Kovarik J (2005) Interferon-gamma, but not interferon-alpha, induces SOCS 3 expression in human melanoma cell lines. Melanoma Res 15: 481–488 PubMed

Kovarik A, Peat N, Wilson D, Gendler SJ, Taylor-Papadimitriou J (1993) Analysis of the tissue-specific promoter of the MUC1 gene. J Biol Chem 268: 9917–9926 PubMed

Kovarik J, Boudny V, Kocak I, Lauerova L, Fait V, Vagundova M (2003) Malignant melanoma associates with deficient IFN-induced STAT 1 phosphorylation. Int J Mol Med 12: 335–340 PubMed

Kovarik P, Mangold M, Ramsauer K, Heidari H, Steinborn R, Zotter A, Levy DE, Muller M, Decker T (2001) Specificity of signaling by STAT1 depends on SH2 and C-terminal domains that regulate Ser727 phosphorylation, differentially affecting specific target gene expression. EMBO J 20: 91–100 PubMed PMC

Lee KY, Anderson E, Madani K, Rosen GD (1999) Loss of STAT1 expression confers resistance to IFN-gamma-induced apoptosis in ME180 cells. FEBS Lett 459: 323–326 PubMed

Lens MB, Dawes M (2002) Interferon alpha therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 20: 1818–1825 PubMed

Lesinski GB, Valentino D, Hade EM, Jones S, Magro C, Chaudhury AR, Walker MJ, Carson III WE (2005) Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy. Cancer Immunol Immunother 54: 815–825 PubMed PMC

Li Z, Metze D, Nashan D, Muller-Tidow C, Serve HL, Poremba C, Luger TA, Bohm M (2004) Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol 123: 737–745 PubMed

Lu C, Rak JW, Kobyashi H, Kerbel RS (1993) Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced-staged lesions. Cancer Res 53: 2708–2711 PubMed

Masuhara M, Sakamoto H, Matsumoto A, Suzuki R, Yasukawa H, Mitsui K, Wakioka T, Tanimura S, Sasaki A, Misawa H, Yokouchi M, Ohtsubo M, Yoshimura A (1997) Cloning and characterization of novel CIS family genes. Biochem Biophys Res Commun 239: 439–446 PubMed

Pansky A, Hildebrand P, Fasler-Kan E, Baselgia L, Ketterer S, Beglinger C, Heim MH (2000) Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer 85: 720–725 PubMed

Ramana CV, Kumar A, Enelow R (2005) Stat1-independent induction of SOCS-3 by interferon-gamma is mediated by sustained activation of Stat3 in mouse embryonic fibroblasts. Biochem Biophys Res Commun 327: 727–733 PubMed

Ransohoff RM (1998) Cellular responses to interferons and other cytokines: the JAK-STAT paradigm. N Engl J Med 338: 616–618 PubMed

Sakai I, Takeuchi K, Yamauchi H, Narumi H, Fujita S (2002) Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood 100: 2926–2931 PubMed

Shuai K, Ziemiecki A, Wilks AF, Harpur AG, Sadowski HB, Gilman MZ, Darnell JE (1993) Polypeptide signaling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins. Nature 366: 580–583 PubMed

Sutherland KD, Lindeman GJ, Choong DYH, Wittlin S, Brentzell L, Phillips W, Campbell IG, Visvader JE (2004) Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene 23: 7726–7733 PubMed

Timofeeva OA, Plisov S, Evseev AA, Peng S, Jose-Kampfner M, Lovvorn HN, Dome JS, Perantoni AO (2006) Serine-phosphorylated STAT1 is a prosurvival factor in Wilms' tumor pathogenesis. Oncogene 25: 7555–7564 PubMed

Weber A, Hengge UR, Bardenheuer W, Tischoff I, Sommerer F, Markwarth A, Dietz A, Wittekind C, Tannapfel A (2005) SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene 24: 6699–6708 PubMed

Wellbrock C, Weisser C, Hassel JC, Fischer P, Becker J, Vetter CS, Behrmann I, Kortylewski M, Heinrich PC, Schartl M (2005) STAT5 contributes to interferon resistance of melanoma cells. Curr Biol 15: 1629–1639 PubMed

Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND, Edmondson S, Devenish RJ, Ralph SJ (1997) Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem 272: 28779–28885 PubMed

Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC, Herman JG (2001) SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 28: 29–35 PubMed